Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose intramuscular ketamine for treatment-resistant anxiety
ACTRN12626000497303Phase 4Not yet recruiting
- Sponsor
- University of Otago
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ketamine in treatment-resistant anxiety (TRA), generalized anxiety disorder (GAD) and Social Anxiety Disorder (SAD), sponsored by University of Otago. Primary endpoints: Change in Functional Connectivity and Change in Anxiety. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
treatment-resistant anxiety (TRA)generalized anxiety disorder (GAD)Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on ACTRN12626000497303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000497303.